人乳头瘤病毒血清阳性率和血清转化率在年轻女性中基线检测九种人乳头瘤病毒类型后。
Human papillomavirus seroprevalence and seroconversion following baseline detection of nine human papillomavirus types in young women.
机构信息
Department of Medicine, Indiana University School of Medicine, Van Nuys Med Science Building, Suite 224, 635 Barnhill Drive, Indianapolis, IN, 46202, USA.
Institut Catala d'Oncologia, IDIBELL, CIBERESP, L'Hospitalet de Llobregat, Granvia de l'Hospitalet 199-203, Barcelona, Catalonia, 08908, Spain.
出版信息
Tumour Virus Res. 2022 Jun;13:200236. doi: 10.1016/j.tvr.2022.200236. Epub 2022 May 4.
BACKGROUND
Estimates of the humoral immune response to incident human papillomavirus (HPV) infections are limited.
METHODS
In this post hoc analysis of 3875 women aged 16-23 years from a 4-valent HPV vaccine trial (NCT00092482), HPV seroprevalence on day 1 was measured with a 9-valent HPV (HPV 6/11/16/18/31/33/45/52/58) competitive Luminex immunoassay and compared with cervical/external genital HPV detection by polymerase chain reaction. In the control group, among women who were HPV DNA‒negative on day 1, seroconversion following initial HPV detection was estimated using Kaplan-Meier methods.
RESULTS
Type-specific HPV seropositivity among women with no day 1 cervical/external genital HPV detection was 0.6%-3.6%. Women with any 9-valent HPV (9vHPV) cervical/external genital detection (796/3875; 20.5%) had concordant seropositivity ranging from 13.4% (HPV 45) to 38.5% (HPV 6). Among women in the control group who were negative for all HPV types on day 1, seroconversion by month 30 after initial detection ranged from 29% (HPV 45) to 75% (HPV 16).
CONCLUSIONS
Humoral immune response to HPV is variable and dynamic, depending on type-specific exposure. This longitudinal analysis provides insight into the relationship between incident infection and seropositivity.
CLINICALTRIALS
gov; NCT00092482 https://clinicaltrials.gov/ct2/show/NCT00092482.
背景
针对新感染人乳头瘤病毒（HPV）的体液免疫反应的评估十分有限。
方法
本研究为四价 HPV 疫苗试验（NCT00092482）的事后分析，共纳入 3875 名 16-23 岁的女性，于第 1 天采用九价 HPV（HPV 6/11/16/18/31/33/45/52/58）竞争性 Luminex 免疫分析法检测 HPV 血清阳性率，并与聚合酶链反应（PCR）检测宫颈/外阴 HPV 进行比较。在对照组中，于第 1 天 HPV DNA 阴性的女性中，使用 Kaplan-Meier 方法评估初次 HPV 检测后的血清转化情况。
结果
第 1 天无宫颈/外阴 HPV 检测的女性中，HPV 血清阳性率为 0.6%-3.6%。任何九价 HPV（9vHPV）宫颈/外阴检测阳性的女性（796/3875；20.5%）均存在 13.4%（HPV 45）至 38.5%（HPV 6）的一致性血清阳性。在第 1 天所有 HPV 类型均为阴性的对照组女性中，初次检测后 30 个月的血清转化率范围为 29%（HPV 45）至 75%（HPV 16）。
结论
HPV 的体液免疫反应具有多样性和动态性，取决于特定的型别暴露。这项纵向分析为新感染与血清阳性之间的关系提供了深入了解。
临床试验
gov；NCT00092482 https://clinicaltrials.gov/ct2/show/NCT00092482。
Zotero 插件